SYRE
Spyre Therapeutics, Inc.
Latest Form 4:Sale$2.4MbyAlbers Jeffrey W. (Director) · filed Aug 11, 2026
Spyre Therapeutics, Inc. (SYRE) has 27 SEC Form 4 filings (80 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Aug 11, 2026.
The most active filer is Chief Executive Officer Turtle Cameron with 10 filings. Insiders have net sold $428.2M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Cameron Turtle
- Employees:125
- HQ:Waltham, MA, US
- IPO:2016-04-07
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$430.9M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Market Cap
$8.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Albers Jeffrey W.First in 8 months | Director | Sale | 23,000 | $2.4M | Aug 11 | SEC ↗ |
| Chief Financial Officer | Sale | 7,500 | $717K | Aug 6 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $1.4M | Aug 6 | SEC ↗ | |
| Chief Financial Officer | Sale | 7,500 | $658K | Jul 3 | SEC ↗ | |
| Chief Medical Officer | Sale | 8,334 | $731K | Jul 3 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $1.3M | Jul 3 | SEC ↗ | |
| Chief Financial Officer | Sale | 15,000 | $1.3M | Jun 27 | SEC ↗ | |
| Director | Sale | 4,684,781 | $399.7M | Jun 24 | SEC ↗ | |
| Director | Sale | 20,000 | $2.0M | Jun 24 | SEC ↗ | |
| Chief Medical Officer | Sale | 8,333 | $625K | Jun 4 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $1.1M | Jun 4 | SEC ↗ | |
| Chief Financial Officer | Sale | 7,500 | $533K | Jun 4 | SEC ↗ | |
| Director | Sale | 80,000 | $6.0M | May 9 | SEC ↗ | |
| Chief Financial Officer | Sale | 12,500 | $892K | May 2 | SEC ↗ | |
| Chief Medical Officer | Sale | 78,333 | $5.6M | May 2 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $1.1M | May 2 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $740K | Apr 3 | SEC ↗ | |
Sloan SheldonFirst filing | Chief Medical Officer | Sale | 7,958 | $398K | Apr 3 | SEC ↗ |
| Chief Financial Officer | Sale | 7,500 | $370K | Apr 3 | SEC ↗ | |
Burrows Scott LFirst in 6 months | Chief Financial Officer | Sale | 2,500 | $102K | Mar 3 | SEC ↗ |
| Chief Executive Officer | Sale | 15,000 | $633K | Mar 3 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $492K | Feb 4 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $460K | Jan 6 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $435K | Dec 3 | SEC ↗ | |
Turtle CameronFirst filing | Chief Executive Officer | Sale | 45,000 | $1.0M | Nov 5 | SEC ↗ |
Burrows Scott LFirst filing | Chief Financial Officer | Sale | 18,428 | $300K | Sep 3 | SEC ↗ |
Related companies
Spyre Therapeutics, Inc. is in the Healthcare sector.